Investing in the Future of Precision Cancer Medicine

Developing a first-in-class, 3rd generation Polo-like Kinase 1 (PLK1) Inhibitor to treat leukemias, lymphomas
and solid tumor cancers

Press Releases

Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012

2019 Archives

Nov 6, 2019
- Results from completed Phase 1b and ongoing Phase 2 trial of onvansertib in relapsed/refractory AML to be presented in oral session
Oct 22, 2019
-- Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5%
Oct 2, 2019
- Significant tumor regression observed with onvansertib in combination with standard-of-care paclitaxel in models of p53-mutated TNBC
Oct 1, 2019
- Trial assessing safety and efficacy of onvansertib in combination with FOLFIRI and Avastin® (bevacizumab) in KRAS-mutated mCRC
Sep 30, 2019
- Administration of onvansertib in combination with standard-of-care chemotherapy is safe and well-tolerated and resulted in anti-leukemic activity that appears to be sustainable over time
Sep 19, 2019
- Phase 1b dose escalation clinical trial confirmed safety, preliminary efficacy and identified the recommended phase 2 dose of onvansertib
Aug 26, 2019
- Trial leads to discovery that onvansertib stops rise in PSA in patients with treatment-resistant, highly-aggressive and difficult-to-treat androgen-receptor variant 7 (AR-V7) tumors
Jul 22, 2019
- Acute Myeloid Leukemia (AML) clinical trial data to be presented in an oral presentation
Jul 15, 2019
Management team to meet with investment institutions, analysts and shareholders in NYC to provide an overview of the Company and its advancing clinical development of onvansertib
Jul 9, 2019
Trial will evaluate safety and efficacy of onvansertib plus FOLFIRI and Avastin® (bevacizumab) for treatment of patients with KRAS-mutated metastatic Colorectal Cancer (mCRC)
May 30, 2019
Conference Call Begins at 11:00 am EDT
May 23, 2019
ONZEALD is currently being evaluated in a Phase 3 trial in patients with metastatic breast cancer and brain metastases
May 13, 2019
Additional funding further extends runway for Trovagene to accelerate clinical development of onvansertib for the treatment of cancers where new therapeutic options are most needed
Apr 23, 2019
Data provides support for clinical evaluation of onvansertib in combination with venetoclax in patients with difficult-to-treat relapsed or refractory acute myeloid leukemia (AML)
Apr 5, 2019
Complete response achieved in 3 of 6 (50%) evaluable patients at the highest doses (27mg/m2 and 40mg/m2) of onvansertib in combination with standard-of-care decitabine
Apr 5, 2019
Investment follows recent receipt of ~$3.2 million from exercise of previously issued warrants
Apr 2, 2019
Early PSA response observed when onvansertib is added to abiraterone (Zytiga®) in 2 of 6 patients to-date; first patient achieves primary efficacy endpoint
Apr 1, 2019
Greatest anti-leukemic activity has been observed in the onvansertib + decitabine arm, with complete response in 2 of 4 (50%) of evaluable patients from the two highest dose levels